Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $88,389.00 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 12,075 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $88,389.00. Following the sale, the chief executive officer now directly owns 819,758 shares of the company’s stock, valued at approximately $6,000,628.56. This represents a 1.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, September 10th, Zhenya Lindgardt sold 25,085 shares of Sera Prognostics stock. The shares were sold at an average price of $7.57, for a total transaction of $189,893.45.

Sera Prognostics Price Performance

Sera Prognostics stock opened at $6.44 on Friday. The firm has a 50 day simple moving average of $7.38 and a 200-day simple moving average of $7.64. Sera Prognostics, Inc. has a 1-year low of $1.67 and a 1-year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the business posted ($0.23) earnings per share. Equities analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds have recently made changes to their positions in SERA. MetLife Investment Management LLC lifted its holdings in Sera Prognostics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock worth $135,000 after buying an additional 9,722 shares in the last quarter. Quest Partners LLC lifted its holdings in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares in the last quarter. Prime Capital Investment Advisors LLC acquired a new stake in Sera Prognostics during the 3rd quarter worth approximately $104,000. SG Americas Securities LLC acquired a new stake in shares of Sera Prognostics in the 3rd quarter valued at $78,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Sera Prognostics in the 2nd quarter valued at $68,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.